Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis

Patent metadata

Field	Value
Publication number	US-9951388-B2
Application number	US-201214115327-A
Country	US
Kind code	B2
Filing date	May 7, 2012
Priority date	May 9, 2011
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

In general, the presently disclosed technology relates to identification of cancer subtypes. More specifically, the technology relates to methods for determining molecular drivers of cancer and/or progression using a multivariate image data and statistical analysis of in-situ molecular markers and morphological characteristics in the same cells of a biological sample suspected of b cancer. This analysis takes place after a single acquisition that obtains the molecular and anatomic morphology data in parallel. The analysis compares specific morphological and molecular markers to known samples exhibiting particular genetic drivers of the cancer. This method provides statistical information that allows for an increased confidence in the identification of specific molecular drivers of the cancer.

First claim

The invention claimed is:

1. An image acquisition method for simultaneously detecting in a single field of view both a genetic rearrangement marker and nuclear morphology in a single cell or single sample containing a population of cells from a tissue, said method comprising:
a. subjecting the single cell or single sample to a fluorescent nuclear stain for making visible sizes of nuclei, shapes of nuclei, and amount of stain contained in nuclei, and subjecting the single cell or single sample to fluorescence in situ hybridization (FISH) for detecting the genetic rearrangement marker using labeled nucleic acids;
b. in a single field of view of the single cell or single sample, with a stabilized light source capable of repeating illumination at a plane of the single cell or single sample with less than 1% variation in absolute illumination level so that variability in brightness levels reflects true stain distribution and with a calibrated quantitative detection (CCD) spectral detection system, acquiring a raw spectral data cube using a rapid series of exposures for a set of wavelengths across a wavelength range from 400 nm to 800 nm, the raw spectral data cube comprises intensities for each wavelength at each pixel;
c. using linear unmixing to deconvolve the raw spectral data cube into specific wavelength channels representing a relative distribution of signal at each pixel, generating individual images for each channel of interest, then generating an image representing nuclear morphology and an image representing the genetic rearrangement marker;
d. calculating for each nucleus except non-glandular nuclei or non-cancer nuclei (i) nuclear roundness; (ii) relative chromatin content; and (iii) status of the genetic rearrangement marker; and
e. comparing the nuclear roundness, relative chromatin content, and status of the genetic rearrangement marker of each cell to nuclear roundness, relative chromatin content, and genetic rearrangement marker data from a library of reference cancer cell populations to determine a cancer sub-type.

2. The method of claim 1 , wherein the genetic rearrangement marker is an ERG rearrangement marker to detect an ERG rearrangement.

3. The method of claim 2 , wherein the ERG rearrangement is an insertion into the ERG gene, or deletion of the 5′ region of ERG.

4. The method of claim 1 , wherein the fluorescent nuclear stain comprises a DAPI stain.

5. The method of claim 1 , wherein nuclear roundness is calculated using a formula (Perimeter) 2 /(4π×area), wherein a value of 1 is for a round nucleus and a value greater than 1 is for a nucleus with less roundness.

Assignees

• Demichelis Francesca
• Garsha Karl
• Miller Phillip C
• Nagle Ray B
• Otter Michael
• Pestano Gary Anthony
• Rubin Mark
• Ventana Med Syst Inc
• Univ Cornell

Inventors

• Demichelis Francesca
• Garsha Karl
• Miller Phillip C
• Nagle Ray B
• Otter Michael
• Pestano Gary Anthony
• Rubin Mark

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• H01M50/572

  Means for preventing undesired use or discharge · CPC title

• H01M2220/20

  Batteries in motive systems, e.g. vehicle, ship, plane · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title